NASDAQ:INFI Infinity Pharmaceuticals (INFI) Stock Forecast, Price & News $0.02 0.00 (0.00%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.2452-Week Range$0.02▼$1.30Volume850,326 shsAverage Volume2.91 million shsMarket Capitalization$2.07 millionP/E RatioN/ADividend YieldN/APrice Target$1.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Infinity Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside6,464.6% Upside$1.50 Price TargetShort InterestHealthy2.43% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 7 Articles This WeekInsider TradingSelling Shares$28,714 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.77 out of 5 stars 3.0 Analyst's Opinion Consensus RatingInfinity Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.50, Infinity Pharmaceuticals has a forecasted upside of 6,464.6% from its current price of $0.02.Amount of Analyst CoverageInfinity Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.43% of the outstanding shares of Infinity Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverInfinity Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Infinity Pharmaceuticals has recently increased by 12.18%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInfinity Pharmaceuticals does not currently pay a dividend.Dividend GrowthInfinity Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INFI. Previous Next 3.1 News and Social Media Coverage News SentimentInfinity Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Infinity Pharmaceuticals this week, compared to 1 article on an average week.Search Interest16 people have searched for INFI on MarketBeat in the last 30 days. This is an increase of 45% compared to the previous 30 days.MarketBeat Follows6 people have added Infinity Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Infinity Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,714.00 in company stock.Percentage Held by InsidersOnly 9.81% of the stock of Infinity Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 22.14% of the stock of Infinity Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Infinity Pharmaceuticals is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Infinity Pharmaceuticals is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Infinity Pharmaceuticals (NASDAQ:INFI) StockInfinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.Read More INFI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INFI Stock News HeadlinesSeptember 19, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Infinity Pharmaceuticals (NASDAQ:INFI)September 18, 2023 | stockhouse.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 21, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.September 18, 2023 | americanbankingnews.comInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Sees Significant Increase in Short InterestSeptember 16, 2023 | prnewswire.comINFINITY DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their OptionsSeptember 16, 2023 | markets.businessinsider.comROSEN, A TOP RANKED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFISeptember 15, 2023 | stockhouse.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 14, 2023 | stockhouse.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 21, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.September 13, 2023 | gurufocus.comDirector Adelene Perkins Sells 410,196 Shares of Infinity Pharmaceuticals Inc (INFI)September 13, 2023 | stockhouse.comSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 13, 2023 | seekingalpha.comInfinity Pharmaceuticals receives delisting determination letter from NasdaqSeptember 12, 2023 | americanbankingnews.comInfinity Pharmaceuticals (NASDAQ:INFI) Coverage Initiated by Analysts at StockNews.comSeptember 11, 2023 | stockhouse.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 6, 2023 | benzinga.comINFI Stockholders Should Contact Robbins LLP for Information About the Class Action Involving Infinity Pharmaceuticals, Inc.September 6, 2023 | stockhouse.comInfinity Shareholder NoticeSeptember 6, 2023 | finanznachrichten.deDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 5, 2023 | finance.yahoo.comThree execs leave Infinity Pharmaceuticals after failed merger, layoffsSeptember 2, 2023 | stockhouse.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAugust 28, 2023 | benzinga.comINFI Stock News: Investors with Significant Losses in Infinity Pharmaceuticals, Inc. Should Contact Robbins LLP About RecoveryAugust 27, 2023 | prnewswire.comROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFIAugust 25, 2023 | markets.businessinsider.comInfinity Shareholder Action ReminderAugust 24, 2023 | businesswire.comInfinity Pharmaceuticals, Inc. (INFI) Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Infinity Pharmaceuticals, Inc. Securities Class ActionAugust 23, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFIAugust 21, 2023 | benzinga.comInfinity Pharmaceuticals, Inc. (INFI) Shareholder Notice: Robbins LLP Reminds Investors of Class Action Filed Against Infinity Pharmaceuticals, Inc.August 20, 2023 | prnewswire.comROSEN, A LEADING LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFIAugust 19, 2023 | businesswire.comINFINITY ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Infinity Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmSee More Headlines Receive INFI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address INFI Company Calendar Last Earnings8/10/2023Today9/21/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INFI CUSIP45665G30 CIK1113148 Webwww.infi.com Phone(617) 453-1000Fax617-453-1001Employees30Year Founded2000Price Target and Rating Average Stock Price Forecast$1.50 High Stock Price Forecast$1.50 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+6,464.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,370,000.00 Net Margins-1,593.93% Pretax Margin-1,593.93% Return on EquityN/A Return on Assets-113.02% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.65 Sales & Book Value Annual Sales$2.59 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / Book-0.11Miscellaneous Outstanding Shares90,760,000Free Float81,857,000Market Cap$2.07 million OptionableOptionable Beta1.38 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMs. Adelene Q. Perkins (Age 63)Chairman & CEO Comp: $701.51kDr. Robert Ilaria Jr. (Age 62)M.D., Chief Medical Officer Comp: $653.8kDr. Lawrence E. Bloch J.D. (Age 57)M.D., Treasurer Comp: $513.61kMs. Melissa HackelVP of Fin.Dr. Stephane Peluso Ph.D. (Age 52)Chief Scientific Officer Mr. Seth A. Tasker J.D. (Age 44)Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. More ExecutivesKey CompetitorsNovaBay PharmaceuticalsNYSE:NBYScopus BioPharmaNASDAQ:SCPSAltamira TherapeuticsNASDAQ:CYTOAllarity TherapeuticsNASDAQ:ALLRHistogenNASDAQ:HSTOView All CompetitorsInsiders & InstitutionsAdelene Q PerkinsSold 410,196 sharesTotal: $28,713.72 ($0.07/share)Renaissance Technologies LLCBought 123,200 shares on 8/11/2023Ownership: 0.398%Carlson Capital L PBought 300,000 shares on 8/10/2023Ownership: 1.446%View All Insider TransactionsView All Institutional Transactions INFI Stock - Frequently Asked Questions Should I buy or sell Infinity Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INFI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INFI, but not buy additional shares or sell existing shares. View INFI analyst ratings or view top-rated stocks. What is Infinity Pharmaceuticals' stock price forecast for 2023? 2 Wall Street analysts have issued twelve-month price targets for Infinity Pharmaceuticals' shares. Their INFI share price forecasts range from $1.50 to $1.50. On average, they anticipate the company's share price to reach $1.50 in the next year. This suggests a possible upside of 6,464.6% from the stock's current price. View analysts price targets for INFI or view top-rated stocks among Wall Street analysts. How have INFI shares performed in 2023? Infinity Pharmaceuticals' stock was trading at $0.5550 on January 1st, 2023. Since then, INFI shares have decreased by 95.9% and is now trading at $0.0229. View the best growth stocks for 2023 here. Are investors shorting Infinity Pharmaceuticals? Infinity Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,210,000 shares, an increase of 12.2% from the August 15th total of 1,970,000 shares. Based on an average trading volume of 3,370,000 shares, the short-interest ratio is presently 0.7 days. View Infinity Pharmaceuticals' Short Interest. When is Infinity Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our INFI earnings forecast. How were Infinity Pharmaceuticals' earnings last quarter? Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) posted its earnings results on Thursday, August, 10th. The biotechnology company reported ($0.11) earnings per share for the quarter. The biotechnology company had revenue of $0.58 million for the quarter. What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO? 10 employees have rated Infinity Pharmaceuticals Chief Executive Officer Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among the company's employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Infinity Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX). What is Infinity Pharmaceuticals' stock symbol? Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI." Who are Infinity Pharmaceuticals' major shareholders? Infinity Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Carlson Capital L P (1.45%), Renaissance Technologies LLC (0.40%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Adelene Q Perkins and Bvf Partners L P/Il. View institutional ownership trends. How do I buy shares of Infinity Pharmaceuticals? Shares of INFI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Infinity Pharmaceuticals' stock price today? One share of INFI stock can currently be purchased for approximately $0.02. How much money does Infinity Pharmaceuticals make? Infinity Pharmaceuticals (NASDAQ:INFI) has a market capitalization of $2.07 million and generates $2.59 million in revenue each year. The biotechnology company earns $-44,370,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. How can I contact Infinity Pharmaceuticals? Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The official website for the company is www.infi.com. The biotechnology company can be reached via phone at (617) 453-1000, via email at irpr_info@infi.com, or via fax at 617-453-1001. This page (NASDAQ:INFI) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Infinity Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.